Madrigal Pharmaceuticals CEO: We're positioned for decades of growth

Key Concepts

• Madrigal Pharma: A pharmaceutical company focused on liver disease treatments.
• Resmetirom (Rezdiffra): The only FDA-approved drug for the treatment of NASH (nonalcoholic steatohepatitis), now referred to as MASLD (metabolic dysfunction-associated steatohepatitic liver disease)
• MASLD (Metabolic Dysfunction-Associated Steatohepatitic Liver Disease): A liver disease associated with metabolic dysfunction.
• GLP-1 (Glucagon-like peptide-1): A class of drugs used to treat type 2 diabetes and obesity.
• Oral GLP-1: A GLP-1 receptor agonist administered orally.
• Weight Loss: A reduction in body weight, often a target in obesity and diabetes treatments.
• Patent Protection: Legal rights granted for an invention, preventing others from making, using, or selling the invention.
• Market Penetration: The extent to which a product is being used by potential customers.
• Adverse Events: Undesirable side effects of a medication.
• Dosing Patent: A patent that protects a specific method or schedule for administering a drug.
• Potentiation: The enhancement of the effect of one drug by another.

Madrigal Pharma's Performance and Market Penetration

• Madrigal Pharma's stock has increased by more than 14% this week due to a strong quarter.
• The demand for Resmetirom (Rezdiffra), the only FDA-approved MASLD treatment drug, is rising.
• Madrigal has secured a global license for an oral GLP-1 drug to combine with Resmetirom into a once-a-day pill.
• Currently, Madrigal has achieved 7% penetration into the diagnosed population of 315,000 individuals.
• The CEO emphasizes that this is just the beginning of the launch, with years of growth ahead.
• MASLD is the number one cause of liver transplants for women in the United States and soon to be number one for men.
• Madrigal is positioned for decades of growth in this market.

Oral GLP-1 Acquisition and Combination Strategy

• Madrigal has acquired exclusive global rights to an oral GLP-1 drug, a derivative of orforglipron.
• The oral GLP-1 is intended for the treatment of type 2 diabetes and obesity.
• The CEO addresses concerns about Eli Lilly's orforglipron data, particularly regarding adverse events and dropout rates.
• Madrigal's strategy focuses on achieving a balance between efficacy, safety, and tolerability.
• The company aims to potentiate the effect of Resmetirom with a modest amount of weight loss (at least 5%) achieved through the oral GLP-1.
• Madrigal is not aiming for the highest amount of weight loss, unlike other oral GLP-1 drugs.
• The combination therapy is designed to maximize the effect for patients while maintaining safety and tolerability.

Patent Protection and Future Strategy

• Madrigal has a new dosing patent that extends to 2045, providing a long runway for continued leadership in the MASLD space.
• The patent allows Madrigal to strategically plan for the future and maintain its competitive advantage.
• The company's strategy involves combining Resmetirom with an oral GLP-1 to enhance efficacy and patient outcomes.

Conclusion

Madrigal Pharma is experiencing significant growth driven by the demand for Resmetirom, the only FDA-approved MASLD treatment. The company's acquisition of an oral GLP-1 drug and its strategy to combine it with Resmetirom demonstrates a forward-thinking approach to addressing the unmet needs in the treatment of MASLD, type 2 diabetes, and obesity. With strong patent protection and a focus on safety and tolerability, Madrigal is well-positioned for long-term growth and market leadership.